SII is the largest manufacturer of BCG vaccine across the world, while Merck & Co Inc (NYSE:MRK) currently is the only manufacturer of BCG (TICE BCG) in the U.S. ImmunityBio plans to conduct ...

However, the approval of Merck’s drug is limited to patients unresponsive to BCG. Although primarily used to prevent tuberculosis, the BCG vaccine is also a standard treatment for some forms of ...

Anktiva becomes another option for BCG-unresponsive BMIBC patients alongside MSD/Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) – approved by the FDA in 2020 – and Ferring Pharma’s ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

However, the Merck and ImmunityBio drugs utilize a different mechanism of action — IBRX’s Anktiva is an IL-15 antibody drug, approved for intravesical use in combination with the BCG vaccine.

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main ... the same class of treatment as Merck's (MRK.N), opens new tab Keytruda, which ...